Hope for Drug-Resistant lung cancer: new combo trials underway

NCT ID NCT02143466

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests two different drug combinations in people with advanced EGFR-mutant lung cancer whose disease has worsened after standard targeted therapy. Participants receive either osimertinib plus savolitinib or osimertinib plus selumetinib. The main goal is to check safety and find the right doses, while also looking for early signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (AZD9291) combined with savolitinib (AZD6094) or selumetinib
What this could lead to: If successful, this could point toward new combination treatments for advanced lung cancer that has stopped responding to standard targeted therapy.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is too soon to know if these combinations will work better than existing options. Side effects from combining drugs are also unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Atlanta, Georgia, 30329, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

New York, New York, 10065, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Nashville, Tennessee, 37232, United States
Research Site

Calgary, Alberta, T2N 4N2, Canada
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Chūōku, 104-0045, Japan
Research Site

Habikino-shi, 583-8588, Japan
Research Site

Hirakata-shi, 573-1191, Japan
Research Site

Kashiwa, 227-8577, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Gdansk, 80-952, Poland
Research Site

Krakow, 31-202, Poland
Research Site

Olsztyn, 10-357, Poland
Research Site

Poznan, 60-569, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Chelyabinsk, 454087, Russia
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Moscow, 115478, Russia
Research Site

Omsk, 644013, Russia
Research Site

Saint Petersburg, 195271, Russia
Research Site

Saint Petersburg, 197002, Russia
Research Site

Saint Petersburg, 197022, Russia
Research Site

Saint Petersburg, 197342, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Cheongju-si, 28644, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Kaohsiung City, 82445, Taiwan
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Kyiv, 03022, Ukraine
Research Site

Vinnytsia, 21029, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.